Intravenous irinotecan plus oral ciclosporin
- PMID: 16372492
- DOI: 10.1016/j.clon.2005.06.009
Intravenous irinotecan plus oral ciclosporin
Abstract
We previously reported a phase I study of intravenous irinotecan plus oral ciclosporin, in which dose-limiting diarrhoea was not observed, supporting the hypothesis that pharmacokinetic modulation of irinotecan by ciclosporin may improve its therapeutic index. We now report results of a further 34 patients treated at the recommended dose. A low rate of diarrhoea of grade 3 or above (3%) was again seen, with useful anti-tumour activity. The regimen is to be formally evaluated as part of a future phase III trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
